European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Nov 1978
Clinical TrialInitial clinical experience of lorcainide (Ro 13-1042), a new antiarrhythmic agent.
Lorcainide is a promising antiarrhythmic agent that belongs to the class of local anesthetics. It was tested in 7 patients with malignant ventricular arrhythmias that were resistant to other antiarrhythmic agents. ⋯ The drug was effective at rest, as assessed by 24-h dynamic electrocardiographic monitoring, and during physical exercise. Longer studies with more patients are warranted, since the drug appears to be a promising antiarrhythmic agent.
-
Eur. J. Clin. Pharmacol. · Sep 1976
Clinical TrialClinical pharmacokinetics of pancuronium bromide.
Plasma concentrations of pancuronium bromide have been studied in seven surgical patients following a 6 mg intravenous bolus injection of the drug for neuromuscular blockade. Concurrently, evoked muscle twitch response was monitored for each patient as a measure of the pharmacodynamic effect of the drug. The plasma decay curve for pancuronium was found to be biphasic and after rigorous statistical analysis the data were interpreted according to a 2-compartment open model. ⋯ The apparent volume of distribution of the central compartment ranged from 62.9 to145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min. At the first sign of recovery from neuro-muscular blockade the mean pancuronium plasma level was found to be 0.218 mcg/ml. The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.
-
Eur. J. Clin. Pharmacol. · Mar 1976
Randomized Controlled Trial Comparative Study Clinical TrialEffect of paracetamol, mephenoxalone and their combination on pain following bone surgery.
Sixty patients suffering moderate postoperative pain after bone surgery were divided randomly into 3 treatment groups on the day following operation. Under double blind conditions they received either 400 mg mephenoxalone, a weak sedative, or 900 mg paracetamol, or the same doses of these drugs simultaneously, three times daily for three days. ⋯ However, during repeated administration over 3 days, the mean effect of the drug combination was slightly better than that of paracetamol or mephenoxalone alone. The drug combination did not induce more sedation or gastrointestinal side effects than either drug alone.